Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer Research

• Publication date

  2001-03-03

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11289159
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Astrocytomas Expression of Fas / APO-1 during the Progression of Updated Version

  2006cited by this paper
• Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells

  2000cited by this paper
• Bag‐1 and Bcl‐2 Gene Transfer in Malignant Glioma: Modulation of Cell Cycle Regulation and Apoptosis

  2000cited by this paper
• Pathology and genetics of tumours of the nervous system.

  2000cited by this paper
• Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.

  2000cited by this paper
• Immune Escape of Tumors in Vivo by Expression of Cellular Flice-Inhibitory Protein

  1999cited by this paper
• The Inhibitor of Death Receptor Signaling, Flice-Inhibitory Protein Defines a New Class of Tumor Progression Factors

  1999cited by this paper
• A Newly Identified Member of Tumor Necrosis Factor Receptor Superfamily (TR6) Suppresses LIGHT-mediated Apoptosis*

  1999influential reference
• Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives

  1999cited by this paper
• Prevention of constitutive TNF receptor 1 signaling by silencer of death domains.

  1999cited by this paper
• Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

  1999influential reference
• Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes.

  1999cited by this paper
• Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells

  1999cited by this paper
• Necrogenesis and Fas/APO-1 (CD95) Expression in Primary (de novo) and Secondary Glioblastomas

  1998cited by this paper
• Maximal Proliferation of Cytotoxic T Lymphocytes Requires Reverse Signaling through Fas Ligand

  1998cited by this paper
• Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer

  1998influential reference
• APO2 ligand: a novel lethal weapon against malignant glioma?

  1998cited by this paper
• Soluble CD95 (Fas/APO-1) in Malignant Glioma: (No) Implications for CD95-based Immunotherapy?

  1998cited by this paper
• CD95 Ligand: Lethal Weapon Against Malignant Glioma?

  1998influential reference
• Death receptors: signaling and modulation.

  1998cited by this paper
• Chemotactic activity of soluble Fas ligand against phagocytes.

  1998cited by this paper
• Inhibition of death receptor signals by cellular FLIP

  1997cited by this paper
• Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.

  1997cited by this paper
• Apoptosis by death factor.

  1997cited by this paper
• Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics

  1997cited by this paper
• Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

  1997cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Fas Ligand Expression in Glioblastoma Cell Lines and Primary Astrocytic Brain Tumors

  1997cited by this paper
• Antitumor effect of locally produced CD95 ligand

  1997cited by this paper
• Up‐regulation of Bax Protein in Degenerating Retinal Ganglion Cells Precedes Apoptotic Cell Death after Optic Nerve Lesion in the Rat

  1997influential reference
• Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

  1996cited by this paper
• Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.

  1996cited by this paper
• Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme

  1996cited by this paper
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*

  1996cited by this paper
• The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.

  1995cited by this paper
• Monokine production by microglial cell clones

  1989cited by this paper

• Death ligand receptor (DLR) signaling: Its non-apoptotic functions in cancer and the consequences of DLR-directed therapies.

  2025cites this paper
• Cell death in glioblastoma and the central nervous system

  2024cites this paper
• ZNF37A downregulation promotes TNFRSF6B expression and leads to therapeutic resistance to concurrent chemoradiotherapy in rectal cancer patients

  2024cites this paper
• Evaluation of the role of serum DcR3 levels in the early clinical prognosis of patients with Crimean-Congo hemorrhagic fever.

  2023cites this paper
• CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways.

  2023cites this paper
• CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma

  2023cites this paper
• A mathematical modeling technique to understand the role of decoy receptors in ligand-receptor interaction

  2023influential citation
• The dual role of the CD95 and CD95L signaling pathway in glioblastoma

  2022cites this paper
• Meta-Analyses of Splicing and Expression Quantitative Trait Loci Identified Susceptibility Genes of Glioma

  2021cites this paper
• Integrative analysis of TNFRSF6B as a potential therapeutic target for pancreatic cancer.

  2021cites this paper
• E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c- FLIP short Running title: E2F1 targets c-FLIP S to induce apoptosis

  2020cites this paper
• Decoy Receptor 3 Promotes Preosteoclast Cell Death via Reactive Oxygen Species-Induced Fas Ligand Expression and the IL-1α/IL-1 Receptor Antagonist Pathway

  2020cites this paper
• CC12 Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Glioblastoma Cell Lines and Mouse Xenograft Model

  2020cites this paper
• Molecular mechanisms of FasL-mediated 'reverse-signaling'.

  2020cites this paper
• Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer

  2020cites this paper
• Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells

  2020cites this paper
• Cancer biology and other disorders: beneficial role of camptothecin and novel derivatives

  2020cites this paper
• How patients with an intact immune system develop head and neck cancer.

  2019cites this paper
• The Genetic Architecture of Gliomagenesis–Genetic Risk Variants Linked to Specific Molecular Subtypes

  2019cites this paper
• Decoy Receptor 3 Expression Is Associated With Wild-Type EGFR Status, Poor Differentiation of Tumor, and Unfavorable Patient Outcome.

  2019cites this paper
• La inactivación de Pim quinasas potencia la muerte celular mediada por el ligando de muerte trail en glioblastoma

  2019cites this paper
• Role of TGFβ3-Smads-Sp1 axis in DcR3-mediated immune escape of hepatocellular carcinoma

  2019cites this paper
• Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells

  2019cites this paper
• Cancer RNome: Evolution and Sustenance

  2018cites this paper
• Anti‐oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient‐derived tumor xenograft model

  2018cites this paper
• Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism

  2018cites this paper
• Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

  2018cites this paper
• Rôle de la protéine immuno-régulatrice PD-L1 sur le métabolisme des cellules tumorales

  2018cites this paper
• fundiInhibition of CD95/CD95L Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

  2018cites this paper
• RAPID AND SPECIFIC DIAGNOSIS OF BACTERIAL SEPSIS IN HIGH RISK PATIENTS

  2017cites this paper
• Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients.

  2017cites this paper
• Mechanisms of Altered Bone Remodeling in Multiple Myeloma

  2017cites this paper
• Screening critical genes associated with malignant glioma using bioinformatics analysis

  2017cites this paper
• Identification and preclinical evaluation of the small molecule, NSC745887, for treating glioblastomas via suppressing DcR3-associated signaling pathways

  2017cites this paper
• Biomarkers for diet in cancer prevention studies

  2016cites this paper
• Effect of DcR3-specific siRNA on cell growth suppression and apoptosis induction in glioma cells via affecting ERK and AKT

  2016cites this paper
• Targeting Programmed Cell Death Using Small‐Molecule Compounds to Improve Potential Cancer Therapy

  2016cites this paper
• Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand‐dependent apoptosis via the alteration of decoy receptor 3

  2016cites this paper
• Cancer Stem Cells and Tumor-Associated Macrophages

  2016cites this paper
• Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and the correlation with DcR3 and ERK1/2.

  2016cites this paper
• Serum decoy receptor 3 is a diagnostic and prognostic biomarker in patients with colorectal cancer

  2016cites this paper
• Expression and clinicopathological implication of DcR3 in lung cancer tissues: a tissue microarray study with 365 cases

  2016cites this paper
• Mechanisms of Immune Evasion by Cancer

  2016cites this paper
• Expression of tumor necrosis factor-α-induced protein 8 in stage III gastric cancer and the correlation with DcR 3 and ERK 1 / 2

  2016cites this paper
• The serologic decoy receptor 3 (DcR3) levels are associated with slower disease progression in HIV-1/AIDS patients.

  2015cites this paper
• Effect of TNFRSF6B neutralization antibody on cell growth suppression and apoptosis induction in glioma cells.

  2015cites this paper
• Systemic and local expression levels of TNF‐like ligand 1A and its decoy receptor 3 are increased in primary biliary cirrhosis

  2014cites this paper
• Amplification of Genomic DNA for Decoy Receptor 3 Predicts Post-Resection Disease Recurrence in Breast Cancer Patients

  2014cites this paper
• Cancer Therapy : Clinical A Phase II , Randomized , Study of Weekly APG 101 þ Reirradiation versus Reirradiation in Progressive Glioblastoma

  2014cites this paper
• Decoy receptor 3 suppresses B cell functions and has a negative correlation with disease activity in rheumatoid arthritis.

  2014cites this paper
• The role of Death Receptor 3 in allergic lung inflammation

  2014cites this paper
• Reciprocal Supportive Interplay between Glioblastoma and Tumor-Associated Macrophages

  2014cites this paper
• Aberrant expression of decoy receptor 3 in human breast cancer: relevance to lymphangiogenesis.

  2014cites this paper
• Death decoy receptor overexpression and increased malignancy risk in colorectal cancer.

  2014cites this paper
• Terapia génica citotóxica para el tratamiento del cáncer cerebral

  2014cites this paper
• Overexpression of DcR3 and Its Significance on Tumor Cell Differentiation and Proliferation in Glioma

  2014influential citation
• A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

  2014cites this paper
• Decoy receptor 3 polymorphisms are not associated with the risk of esophageal cancer in a Chinese population

  2014cites this paper
• CD95 signaling in cancer treatment.

  2014cites this paper
• Cloning, expression, and characterization of TNFSF14 (LIGHT) gene in mefugu, Takifugu obscurus

  2013cites this paper
• HLA-dependent tumour development: a role for tumour associate macrophages?

  2013cites this paper
• The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma

  2013cites this paper
• by decoy receptor 3 Epigenetic control of MHC-II expression in tumor-associated macrophages

  2013cites this paper
• Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc 1 and enhancing cell apoptosis

  2013cites this paper
• Cloning, expression, and characterization of TNFSF14 (LIGHT) gene in mefugu, Takifugu obscurus

  2013cites this paper
• ‘Decoy’ and ‘non-decoy’ functions of DcR3 promote malignant potential in human malignant fibrous histiocytoma cells

  2013cites this paper
• Harnessing Death Receptor Signaling for Cancer Treatment

  2013cites this paper
• Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.

  2013cites this paper
• The role of Death Receptor 3 in the accumulation of immune cells in inflammatory disease

  2013cites this paper
• 99% circulating tumor cells with 90% accuracy Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to

  2013cites this paper
• Targeting NF-TLR 2-Mediated B Cell Activation by Decoy Receptor 3 Suppresses

  2012cites this paper
• TNFSF15 Modulates Neovascularization and Inflammation

  2012cites this paper
• FunciSNP: an R/bioconductor tool integrating functional non-coding data sets with genetic association studies to identify candidate regulatory SNPs

  2012cites this paper
• Overexpression of decoy receptor 3 in synovial tissues of inflammatory arthritis.

  2012cites this paper
• Decoy Receptor 3 Suppresses TLR2-Mediated B Cell Activation by Targeting NF-κB

  2012cites this paper
• Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer

  2012influential citation
• Tumor-Associated Macrophages Progression via Induction of Decoy Receptor 3 Enhances Tumor

  2012cites this paper
• Decoy Receptor 3 Enhances Tumor Progression via Induction of Tumor-Associated Macrophages

  2012cites this paper
• Investigating procaspase-3 as a potential therapeutic target in canine osteosarcoma

  2012cites this paper
• Mechanisms of immune evasion by gliomas.

  2012cites this paper
• Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis.

  2012cites this paper
• Isolation and characterization of LIGHT (TNFSF14) gene homologue in zebrafish (Danio rerio).

  2012cites this paper
• Fine mapping analysis of a region of 20q13.33 identified five independent susceptibility loci for glioma in a Chinese Han population.

  2012cites this paper
• Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.

  2011cites this paper
• Immunosuppression associée à l’enzyme interleukine-4 induced gene 1 (IL4I1) : régulation de l’expression dans les cellules humaines et rôle dans l’échappement tumoral à la réponse immune dans un modèle murin

  2011cites this paper
• APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo.

  2011cites this paper
• Chemotherapie bei Gliomen

  2011cites this paper
• Tumor Evasion from T Cell Surveillance

  2011cites this paper
• Expression of DcR3 and Its Effects in Kaposi’s Sarcoma-Associated Herpesvirus-Infected Human Endothelial Cells

  2011cites this paper
• RGS4, CD95L and B7H3: Targeting evasive resistance and the immune privilege of glioblastoma

  2011cites this paper
• Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System

  2011cites this paper
• Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.

  2011cites this paper
• Upregulation and nuclear localization of TNF‐like Cytokine 1A (TL1A) and its receptors DR3 and DcR3 in psoriatic skin lesions

  2011cites this paper
• Decoy receptor 3 expression in esophageal squamous cell carcinoma: correlation with tumour invasion and metastasis

  2011cites this paper
• Evaluation d'un protocole préclinique d'immunothérapie dirigé contre les tumeurs cérébrales et du potentiel de présentation antigénique croisée des cellules microgliales adultes

  2011cites this paper
• Decoy Receptor 3 Attenuates Collagen-induced Arthritis by Modulating T Cell Activation and B Cell Expansion

  2011cites this paper
• Anàlisi “ex vivo” de mecanismes d’inducció d’apoptosi i resistència al tractament en gliomes malignes

  2011cites this paper
• Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas.

  2011cites this paper
• Genetics of glioblastoma: a window into its imaging and histopathologic variability.

  2011cites this paper
• Targeting Apoptosis Signaling Pathways for Anticancer Therapy

  2011cites this paper